CHRFAM7A

Apr 20, 2026 - 09:07
0 0
CHRFAM7A

finished clinical significance section, cited sentences.

← Previous revision Revision as of 03:36, 20 April 2026
Line 34: Line 34:


== Function ==
== Function ==
CHRFAM7A functions as a dominant negative regulator to the ɑ7 nicotinic acetylcholine receptor. Its protein product dupɑ7 binds with ɑ7 to form a heteromeric receptor. This results in a hypomorphic receptor formation reducing acetylcholine microscopic currents, channel opening, and calcium influx. In some lung cancers, the receptors hypomorphic response to nicotine may decrease [[Cell proliferation|cell proliteration]], [[Cell migration|migration]], and [[Epithelial–mesenchymal transition|EMT]].
CHRFAM7A functions as a dominant negative regulator to the ɑ7 nicotinic acetylcholine receptor. Its protein product dupɑ7 binds with ɑ7 to form a heteromeric receptor. This results in a hypomorphic receptor formation reducing acetylcholine microscopic currents, channel opening, and calcium influx. In some lung cancers, the receptors hypomorphic response to nicotine may decrease [[cell proliferation]], [[Cell migration|migration]], and [[Epithelial–mesenchymal transition|EMT]].


The presence of the direct allele can reduce therapeutic response to acetylcholine inhibitors because of its hypomorphism. CHRFAM7A is expressed rapidly in human [[White blood cell|leukocytes]] and regulated immune response through modulation of [[NF-κB|NF-kB]] activation and translocation. This leads to the release of inflammatory [[Cytokine|cytokines]] including IL-6, IL-1ß, and TNF-ɑ.
The presence of the direct allele can reduce therapeutic response to acetylcholine inhibitors because of its hypomorphism. CHRFAM7A is expressed rapidly in human [[White blood cell|leukocytes]] and regulated immune response through modulation of [[NF-κB|NF-kB]] activation and translocation. This leads to the release of inflammatory [[Cytokine|cytokines]] including IL-6, IL-1ß, and TNF-ɑ.


CHRFAM7A effects neuronal structure through [[actin cytoskeleton]] reorganization by acting as an upstream regulator of [[RAC1|Rac1]]. This promotes the shift from [[filopodia]] to [[Lamellipodium|lamellipodia]] membrane structures effecting [[cell bodies]], [[growth cone]], and [[Dendritic spine|dendritic spines]] which may lead to more an increase in brain efficiency and neuron connection. It has also been shown to lessen [[amyloid beta]] uptake reducing [[neurotoxicity]] in humans.
CHRFAM7A effects neuronal structure through [[actin cytoskeleton]] reorganization by acting as an upstream regulator of [[RAC1|Rac1]]. This promotes the shift from [[filopodia]] to [[Lamellipodium|lamellipodia]] membrane structures affecting [[cell bodies]], [[growth cone]], and [[Dendritic spine|dendritic spines]] which may lead to an increase in brain efficiency and neuron connection. It has also been shown to lessen [[amyloid beta]] uptake reducing [[neurotoxicity]] in humans.


== Clinical Significance ==
== Clinical Significance ==
CHRFAM7A is absent in standard [[Animal models|preclinical models]] such as [[Animal model of schizophrenia|rodents]] causing a translation gap in drugs targeting the ɑ7 nicotinic acetylcoline receptor. The translation gap is also influenced by the presence of direct alleles that produce a hypomorphic receptor. These factors are not usually accounted for in preclinical screenings, it has been suggested that failed clinical trials should be reproduced so models carry CHRFAM7A and can model human drug responses.

CHRFAM7A also plays a role in pharmacogenetics. The presence of the direct allele has been shown to reduce therapeutic treatment such as acetylcholine inhibitors. The direct allele also reduces neuronal uptake of Amyloid beta which can be protective during early stages of Alzheimer's disease. The △2bp polymorphism in exon 6 has been linked as a risk factor for P50 auditory sensory gating deficits which is also linked to schizophrenia.

CHRFAM7A is present in inflammatory and immune related conditions. In patients with sepsis, a high CHRFAM7A to CHRNA7 ratio in their blood is associated with poor clinical outcomes and increased mortality rates. In contrast, reduced expression is associated with elevated levels of inflammation and condition severity in COVID-19. In spinal cord injuries, the presence of △2bp is associated with increased inflammatroy cytokine levels and higher neuropathic pain. In cell lung carcinomas, the gene acts as a protective factor by reducing nicotine induced cell proliferation and inhibits tumor progression.

In healthy individuals, CHRFAM7A has been linked to brain efficiency and cognitive performance. Neuroimaging suggest carries have smaller whole brain volumes but have higher cognative function.

==References==
==References==
{{reflist}}
{{reflist}}
Read More